Long-term chemotherapy-related cardiovascular morbidity

Cancer Treatment Reviews

Volumn 26, Issue 6, 2000, Pages 429-447

  Meinardi, M T ^a   Gietema, J A ^a   Van Veldhuisen, D J ^a   Van der Graaf, W T A ^a   De Vries, E G E ^a   Sleijfer, D T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiotoxicity; Chemotherapy; Long term; Side effect; Vascular toxicity

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RAZOXANE; TAMOXIFEN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADULT; BREAST CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COLON CANCER; GERM CELL TUMOR; HEART PROTECTION; HUMAN; LIFE EXPECTANCY; LYMPHOMA; METABOLIC DISORDER; METASTASIS; REVIEW; TESTIS CANCER;

EID: 0034500761     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0175     Document Type: Review

References (191)

1. Doxorubicin-induced cardiomyopathy
2. Cardiotoxicity of the antiproliferative compound fluorouracil
3. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
4. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
5. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: A series of 15 patients
6. Combined modality therapy of solic tumours
7. International Germ Cell Consensus Classification: A prognostic factor - Based staging system for metastatic germ cell cancers
8. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture
9. The role of maintenance therapy in disseminated testicular cancer
10. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
11. Testicular germ-cell cancer
12. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis
13. Severe vascular toxicity associated with cisplatin-based chemotherapy
14. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer
15. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy
16. Fatal cerebrovascular accident associated with chemotherapy for testicular cancer
17. Cisplatin and hypomagnesemia
18. Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease
19. Myocardial infarction following vinblastine treatment
20. Etoposide-related myocardial infarction
21. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy
22. Thromboembolic events during combination chemotherapy for germ cell-malignancy
23. Pulmonary emboli as a complication of germ cell cancer treatment
24. Thromboembolic events during combination chemotherapy for germ cell malignancy
25. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy
26. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy
27. Apparent myocardial ishemia associated with vinblastine administration
28. Cisplatin-based chemotherapy and acute cerebrovascular events
29. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer
30. The pathogenesis of bloemycininduced pulmonary fibrosis in mice
31. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: Not only a bleomycin effect
32. Natural course of bleomycin-induced pneumonitis. A follow-up study
33. Vascular toxicity associated with antineoplastic agents
34. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells
35. Bleomycin stimulates production of transforming growth factor-beta by rat pulmonary artery endothelial cells
36. Albuminuria reflects widespread vascular damage. The Steno hypothesis
37. Microalbuminuria and endothelial dysfunction in essential hypertension
38. Treatment related cardiovascular morbidity in long-term survivors of metastatic testicular cancer
39. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity
40. Toxicity of treatment of germ cell tumors
41. Magnesium deficiency and hypertension: Correlation between magnesium-deficient diets and microcirculatory changes in situ
42. Magnesium and blood pressure. I. Animal studies
43. Magnesium and blood pressure. II. Clinical studies
44. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin
45. Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: Possible association with severe coronary artery disease
46. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up
47. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin
48. Evaluation of long-term toxicity after chemotherapy for testicular cancer
49. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer
50. Raynaud's phenomenon
51. Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma
52. Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer
53. Long-term somatic side-effects and morbidity in testicular cancer patients
54. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer
55. Long-term sequelae of treatment for testicular germ cell tumours
56. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer
57. Bleomycin and Raynaud's phenomenon
58. Raynaud's phenomenon after bleomycin treatment
59. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer
60. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold
61. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy
62. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer
63. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin
64. Renovascular hypertension after combination chemotherapy for testicular cancer
65. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors
66. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study
67. Probability of stroke: A risk profile from the Framingham Study
68. Hypercholesterolemia after chemotherapy for testis cancer
69. Decreases in serum cholesterol levels in advanced lung cancer
70. Cholesterolemia in colorectal cancer
71. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate
72. Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line
73. Hypocholesterolaemic factor from gallbladder cancer cells
74. Endocrinological late effects after chemotherapy for testicular cancer
75. Pituitary and testicular hormonal function after treatment for germ cell tumours
76. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men
77. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance
78. Elevated serum lipids in hypogonadal men with and without hyperprolactinemia
79. Body-mass index and mortality in a prospective cohort of U.S. adults
80. Interrelation between plasma testosterone and plasma insulin in healthy adult men: The Telecom Study
81. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey
82. Banting lecture 1988. Role of insulin resistance in human disease
83. Hodgkin's disease
84. Late complications after Hodgkin's disease
85. Combination chemotherapy in the treatment of advanced Hodgkin's disease
86. ABVD chemotherapy in the treatment of Hodgkin's disease
87. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
88. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
89. Advances and future challenges in non-Hodgkin's lymphoma
90. Clinical spectrum of anthracycline, antibiotic cardiotoxicity
91. Anthracycline-induced cardiotoxicity
92. Case report of a lethal cardiac toxic effect following high-dose cyclophosphamide
93. Cyclophosphamide toxicity. Characterising and avoiding the problem
94. Constrictive pericarditis after high-dose chemotherapy
95. Cardiotoxicity associated with high-dose cyclophosphamide therapy
96. Cardiac changes with cyclophosphamide
97. Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin
98. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens
99. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations
100. Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease
101. Myocardial infarction in young patients with Hodgkin's disease - Potential pathogenic role of radiotherapy, chemotherapy, and splenectomy
102. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
103. Deep venous thrombosis during therapy for Hodgkin's disease
104. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma
105. Risk factors for doxorubicin-induced congestive heart failure
106. Late, late doxorubicin cardiotoxicity
107. Epidemiology of anthracycline cardiotoxicity in children and adults
108. The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic
109. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy
110. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results
111. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation
112. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults
113. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas
114. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review
115. Adriamycin cardiomyopathy - Risk factors
116. Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin
117. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease
118. Radiation therapy-induced cardiac injury
119. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
120. Coronary artery disease mortality in patients treated for Hodgkin's disease
121. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols
122. Pulmonary veno-occlusive disease. Entity or syndrome?
123. Pulmonary veno-occlusive disease following therapy for malignant neoplasms
124. Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. Case reports
125. Menopause and coronary heart disease. The Framingham Study
126. The protective effects of estrogen on the cardiovascular system
127. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
128. Influence of bilateral oophorectomy upon lipid metabolism
129. Effects of bilateral oophorectomy on lipoprotein metabolism
130. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy
131. Serum lipids in patients with Hodgkin's disease in complete remission
132. Combination chemotherapy as an adjuvant treatment in operable breast cancer
133. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
134. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer
135. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
136. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
137. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
138. 5-Fluorouracil related toxic myocarditis: Case reports and pathological confirmation
139. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart
140. Profound, yet reversible, heart failure secondary to 5-fluorouracil
141. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil
142. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer
143. Myocardiotoxicity of 5 fluorouracil
144. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens
145. 5-Fluorouracil cardiotoxicity: A critical review
146. Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study
147. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture
148. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy
149. 5-Fluorouracil cardiotoxicity
150. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
151. Venous thrombosis during multimodal treatment of primary breast carcinoma
152. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity
153. Early and delayed clinical cardiotoxicity of doxorubicin
154. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
155. Cardiac sequelae in operable breast cancer patients after CMF ± doxorubicin (A) ± irradiation
156. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer
157. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy
158. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries
159. Cardiac doses in post-operative breast irradiation
160. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation
161. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials
162. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer
163. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast-cancer. Long-term follow-up results of a randomised trial
164. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
165. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer
166. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
167. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
168. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
169. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
170. Effect of tamoxifen on serum lipid metabolism
171. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer
172. Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use
173. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery
174. Tamoxifen and hypertriglyceridemia
175. Prolongation of the disease-free interval in surgically treated rectal carcinoma
176. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
177. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: A one-year follow-up study
178. 5-Fluorouracil-induced Raynaud's phenomenon
179. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
180. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
181. Cardiotoxicity in patients receiving transtuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
182. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
183. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
184. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
185. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
186. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography
187. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group
188. Detection of anthracycline-induced cardiotoxicity
189. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
190. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A post hoc analysis of the studies of left ventricular dysfunction
191. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women